| Autor: |
Brennecke, Benjamin, Gazzi, Thais, Atz, Kenneth, Fingerle, Jürgen, Kuner, Pascal, Schindler, Torsten, Weck, Guy de, Nazaré, Marc, Grether, Uwe |
| Zdroj: |
Pharmaceutical Patent Analyst; June 2021, Vol. 10 Issue: 3 p111-163, 53p |
| Abstrakt: |
The G-protein-coupled cannabinoid receptor type 2 (CB2R) is a key element of the endocannabinoid (EC) system. EC/CB2R signaling has significant therapeutic potential in major pathologies affecting humans such as allergies, neurodegenerative disorders, inflammation or ocular diseases. CB2R agonism exerts anti-inflammatory and tissue protective effects in preclinical animal models of cardiovascular, gastrointestinal, liver, kidney, lung and neurodegenerative disorders. Existing ligands can be subdivided into endocannabinoids, cannabinoid-like and synthetic CB2R ligands that possess various degrees of potency on and selectivity against the cannabinoid receptor type 1. This review is an account of granted CB2R ligand patents from 2010 up to the present, which were surveyed using Derwent Innovation®. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
